ADMA Biologics, Inc. (ADMA)
USD 23.52
(1.07%)
USD 23.52
(1.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 193.97 Million USD | -1.28% |
| 2022 | 196.48 Million USD | 45.46% |
| 2021 | 135.08 Million USD | 13.11% |
| 2020 | 119.42 Million USD | 18.36% |
| 2019 | 100.89 Million USD | 46.0% |
| 2018 | 69.1 Million USD | 2.1% |
| 2017 | 67.68 Million USD | 140.51% |
| 2016 | 28.14 Million USD | 22.93% |
| 2015 | 22.89 Million USD | 7.89% |
| 2014 | 21.21 Million USD | 103.9% |
| 2013 | 10.4 Million USD | 69.72% |
| 2012 | 6.13 Million USD | 62353.38% |
| 2011 | 9818.00 USD | -20.55% |
| 2010 | 12.35 Thousand USD | -99.86% |
| 2009 | 8.68 Million USD | 228.22% |
| 2008 | 2.64 Million USD | -81.93% |
| 2007 | 14.65 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 197.16 Million USD | 1.65% |
| 2024 Q2 | 188.13 Million USD | -4.58% |
| 2023 Q2 | 196.26 Million USD | 0.58% |
| 2023 Q3 | 197.55 Million USD | 0.66% |
| 2023 Q1 | 195.13 Million USD | -0.69% |
| 2023 FY | 193.97 Million USD | -1.28% |
| 2023 Q4 | 193.97 Million USD | -1.81% |
| 2022 Q1 | 181.09 Million USD | 34.07% |
| 2022 Q3 | 200.17 Million USD | 9.66% |
| 2022 FY | 196.48 Million USD | 45.46% |
| 2022 Q4 | 196.48 Million USD | -1.84% |
| 2022 Q2 | 182.53 Million USD | 0.79% |
| 2021 Q4 | 135.08 Million USD | -0.57% |
| 2021 FY | 135.08 Million USD | 13.11% |
| 2021 Q1 | 123.16 Million USD | 3.13% |
| 2021 Q2 | 121.22 Million USD | -1.58% |
| 2021 Q3 | 135.86 Million USD | 12.08% |
| 2020 Q3 | 118.6 Million USD | 3.43% |
| 2020 Q2 | 114.66 Million USD | 0.42% |
| 2020 Q1 | 114.18 Million USD | 13.17% |
| 2020 FY | 119.42 Million USD | 18.36% |
| 2020 Q4 | 119.42 Million USD | 0.69% |
| 2019 Q2 | 96.36 Million USD | 41.55% |
| 2019 Q4 | 100.89 Million USD | -0.75% |
| 2019 FY | 100.89 Million USD | 46.0% |
| 2019 Q1 | 68.08 Million USD | -1.48% |
| 2019 Q3 | 101.66 Million USD | 5.49% |
| 2018 Q2 | 65.99 Million USD | -3.11% |
| 2018 FY | 69.1 Million USD | 2.1% |
| 2018 Q4 | 69.1 Million USD | -0.05% |
| 2018 Q1 | 68.11 Million USD | 0.63% |
| 2018 Q3 | 69.13 Million USD | 4.77% |
| 2017 Q4 | 67.68 Million USD | 13.15% |
| 2017 Q3 | 59.82 Million USD | 5.03% |
| 2017 Q2 | 56.95 Million USD | 100.88% |
| 2017 Q1 | 28.35 Million USD | 0.75% |
| 2017 FY | 67.68 Million USD | 140.51% |
| 2016 Q3 | 27.64 Million USD | -0.64% |
| 2016 Q1 | 23.05 Million USD | 0.7% |
| 2016 Q2 | 27.82 Million USD | 20.7% |
| 2016 Q4 | 28.14 Million USD | 1.79% |
| 2016 FY | 28.14 Million USD | 22.93% |
| 2015 Q3 | 22.9 Million USD | 12.97% |
| 2015 Q1 | 20.49 Million USD | -3.4% |
| 2015 Q2 | 20.28 Million USD | -1.06% |
| 2015 FY | 22.89 Million USD | 7.89% |
| 2015 Q4 | 22.89 Million USD | -0.07% |
| 2014 Q2 | 15.58 Million USD | -2.91% |
| 2014 Q4 | 21.21 Million USD | 32.27% |
| 2014 Q3 | 16.04 Million USD | 2.96% |
| 2014 FY | 21.21 Million USD | 103.9% |
| 2014 Q1 | 16.04 Million USD | 54.21% |
| 2013 Q1 | 7.41 Million USD | 20.96% |
| 2013 Q3 | 9.43 Million USD | 5.31% |
| 2013 Q4 | 10.4 Million USD | 10.27% |
| 2013 FY | 10.4 Million USD | 69.72% |
| 2013 Q2 | 8.96 Million USD | 20.84% |
| 2012 Q2 | 1.22 Million USD | -2.37% |
| 2012 FY | 6.13 Million USD | 62353.38% |
| 2012 Q4 | 6.13 Million USD | 279.02% |
| 2012 Q3 | 1.61 Million USD | 31.73% |
| 2012 Q1 | 1.25 Million USD | 23608.22% |
| 2011 Q1 | 5818.00 USD | 20.76% |
| 2011 Q4 | 5306.00 USD | -45.91% |
| 2011 FY | 9818.00 USD | -20.55% |
| 2011 Q3 | 9809.00 USD | -0.09% |
| 2011 Q2 | 9818.00 USD | 68.75% |
| 2010 Q2 | 12.35 Thousand USD | -99.58% |
| 2010 Q4 | 4818.00 USD | -99.87% |
| 2010 Q3 | 3.61 Million USD | 29184.67% |
| 2010 Q1 | 2.93 Million USD | -57.13% |
| 2010 FY | 12.35 Thousand USD | -99.86% |
| 2009 Q2 | 8.68 Million USD | -14.05% |
| 2009 FY | 8.68 Million USD | 228.22% |
| 2009 Q4 | 6.84 Million USD | -26.17% |
| 2009 Q3 | 9.27 Million USD | 6.7% |
| 2009 Q1 | 10.1 Million USD | 25.91% |
| 2008 Q4 | 8.02 Million USD | 0.0% |
| 2008 Q1 | 6.56 Million USD | -25.24% |
| 2008 FY | 2.64 Million USD | -81.93% |
| 2008 Q2 | 2.64 Million USD | -59.7% |
| 2007 Q4 | 8.78 Million USD | 12.58% |
| 2007 Q1 | 16.66 Million USD | 84.47% |
| 2007 Q2 | 14.65 Million USD | -12.07% |
| 2007 FY | 14.65 Million USD | 0.0% |
| 2007 Q3 | 7.8 Million USD | -46.73% |
| 2006 Q4 | 9.03 Million USD | -19.73% |
| 2006 Q3 | 11.25 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Absci Corporation | 58.3 Million USD | -232.698% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 45.027% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 95.211% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -5913.318% |
| Apollomics, Inc. | 14.15 Million USD | -1270.565% |
| 180 Life Sciences Corp. | 5.38 Million USD | -3500.677% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -3604.66% |
| Bicycle Therapeutics plc | 224.41 Million USD | 13.563% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -605.085% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -48.972% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -279.578% |
| Chimerix, Inc. | 19.74 Million USD | -882.406% |
| CRISPR Therapeutics AG | 346.76 Million USD | 44.062% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 2.191% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -118.291% |
| Fortress Biotech, Inc. | 165.93 Million USD | -16.896% |
| Fortress Biotech, Inc. | 165.93 Million USD | -16.896% |
| Gritstone bio, Inc. | 125.91 Million USD | -54.048% |
| Allakos Inc. | 74.79 Million USD | -159.35% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 24.516% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -182.11% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 83.977% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1240.261% |
| Innoviva, Inc. | 568.55 Million USD | 65.882% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -27414.99% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1716.22% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -637.72% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -14829.948% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1375.103% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -688.328% |
| ImmuCell Corporation | 18.81 Million USD | -930.963% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -587.225% |
| Incyte Corporation | 1.59 Billion USD | 87.818% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -248.907% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -47924.798% |
| Mustang Bio, Inc. | 17.61 Million USD | -1000.948% |
| MiMedx Group, Inc. | 96.33 Million USD | -101.366% |
| MEI Pharma, Inc. | 8.35 Million USD | -2221.676% |
| MacroGenics, Inc. | 154.2 Million USD | -25.789% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -10937.713% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1115.236% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -6208.474% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -25.842% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 72.192% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -127.25% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -3082.021% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -3741.109% |
| NextCure, Inc. | 14.99 Million USD | -1193.432% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -613.961% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -4699.01% |
| Onconetix, Inc. | 23.18 Million USD | -736.793% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2805.137% |
| Opthea Limited | 264.6 Million USD | 26.691% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -244.97% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1502.485% |
| PDS Biotechnology Corporation | 33.25 Million USD | -483.226% |
| Precigen, Inc. | 41.64 Million USD | -365.796% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1527.042% |
| Prime Medicine, Inc. | 60.78 Million USD | -219.144% |
| PureTech Health plc | 125.58 Million USD | -54.46% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -162.958% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.271% |
| Replimune Group, Inc. | 113.21 Million USD | -71.336% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -3385.709% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -32.98% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -5396.804% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 26.075% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2835.792% |
| Sesen Bio, Inc. | 30.98 Million USD | -526.052% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -135.314% |
| Solid Biosciences Inc. | 38.45 Million USD | -404.384% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -230.543% |
| SciSparc Ltd. | 1.59 Million USD | -12061.505% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 39.588% |
| TG Therapeutics, Inc. | 169.08 Million USD | -14.721% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -296.42% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -13333.241% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 67.017% |
| UroGen Pharma Ltd. | 243.52 Million USD | 20.346% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -213.704% |
| XOMA Corporation | 145.58 Million USD | -33.244% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -55.634% |
| AbCellera Biologics Inc. | 335.77 Million USD | 42.231% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1884.612% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1266.509% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -451.427% |
| Precision BioSciences, Inc. | 140.92 Million USD | -37.65% |
| Dyadic International, Inc. | 2.34 Million USD | -8187.267% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -4593.346% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1092.744% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2067.33% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -523.898% |
| IGM Biosciences, Inc. | 220.17 Million USD | 11.9% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -101.724% |
| Acelyrin, Inc. | 86.35 Million USD | -124.631% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -294.453% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -48.405% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -5397.056% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -28.555% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -28.027% |
| Senti Biosciences, Inc. | 52.57 Million USD | -268.979% |
| Mesoblast Limited | 188.79 Million USD | -2.743% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -7.295% |
| ChromaDex Corporation | 26.5 Million USD | -631.764% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2166.818% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 28.76% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -11847.16% |
| Seer, Inc. | 39.36 Million USD | -392.763% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 44.192% |
| Novavax, Inc. | 2.57 Billion USD | 92.459% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -2421.125% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -40.766% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -952.787% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -104.02% |
| Celcuity Inc. | 51.45 Million USD | -277.018% |
| ContextLogic Inc. | 206 Million USD | 5.837% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 60.137% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -171.371% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 97.466% |
| Amarin Corporation plc | 279.58 Million USD | 30.621% |
| AnaptysBio, Inc. | 364.28 Million USD | 46.752% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1436.931% |
| Aptorum Group Limited | 5.25 Million USD | -3590.045% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 73.971% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 59.452% |
| Ardelyx, Inc. | 130.76 Million USD | -48.342% |
| Celularity Inc. | 102.92 Million USD | -88.456% |
| Omeros Corporation | 403.25 Million USD | 51.897% |
| Humacyte, Inc. | 114.67 Million USD | -69.15% |
| Immunocore Holdings plc | 228.15 Million USD | 14.982% |
| IO Biotech, Inc. | 17.55 Million USD | -1004.899% |
| GT Biopharma, Inc. | 6.63 Million USD | -2824.408% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1011.483% |
| Summit Therapeutics Inc. | 125.25 Million USD | -54.862% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -9816.973% |
| Pulmatrix, Inc. | 15.96 Million USD | -1115.16% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 22.66% |
| Evogene Ltd. | 17.99 Million USD | -978.243% |
| CorMedix Inc. | 11.91 Million USD | -1527.653% |
| BioLineRx Ltd. | 50.7 Million USD | -282.581% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1970.844% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -3330.775% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 92.873% |
| scPharmaceuticals Inc. | 57.26 Million USD | -238.758% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -762.077% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -68.951% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1716.22% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2835.792% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -331.393% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -6658.746% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2752.588% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -182.036% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -930.362% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -315.02% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1465.835% |
| Daré Bioscience, Inc. | 26.32 Million USD | -636.715% |
| bluebird bio, Inc. | 424.62 Million USD | 54.318% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 89.737% |
| DBV Technologies S.A. | 42.8 Million USD | -353.215% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -51.792% |
| Galecto, Inc. | 5.89 Million USD | -3189.959% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1946.376% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -606.987% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 26.633% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2710.402% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 23.238% |
| Clene Inc. | 38.95 Million USD | -398.0% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -1.952% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1127.02% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1657.079% |
| Soligenix, Inc. | 7.27 Million USD | -2566.372% |
| Century Therapeutics, Inc. | 175.94 Million USD | -10.251% |
| Kura Oncology, Inc. | 51.66 Million USD | -275.471% |
| Surrozen, Inc. | 8.14 Million USD | -2281.535% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -59.938% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2832.873% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 23.208% |
| Autolus Therapeutics plc | 263.9 Million USD | 26.498% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1750.563% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -313.604% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -167.306% |
| GRI Bio, Inc. | 2.69 Million USD | -7092.288% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -23859.93% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -437.956% |
| INmune Bio, Inc. | 18.86 Million USD | -928.396% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 24.37% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -628.089% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -7035.652% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -5308.474% |
| Jaguar Health, Inc. | 45.86 Million USD | -322.919% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -5813.423% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -231.838% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -288.496% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 26.728% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 76.431% |
| Verastem, Inc. | 71.18 Million USD | -172.496% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -402.815% |
| Histogen Inc. | 5.69 Million USD | -3304.88% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -4323.016% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 38.848% |
| Surrozen, Inc. | 8.14 Million USD | -2281.535% |
| Organovo Holdings, Inc. | 2.74 Million USD | -6958.806% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -61703.746% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -23358.927% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -53.068% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1693.817% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -7339.599% |
| Kronos Bio, Inc. | 54.2 Million USD | -257.883% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1271.049% |
| Synaptogenix, Inc. | 5.52 Million USD | -3408.04% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2817.81% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 14.485% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -14.031% |
| Exelixis, Inc. | 678.44 Million USD | 71.409% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -18.245% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 67.356% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1221.723% |
| ESSA Pharma Inc. | 3.49 Million USD | -5449.987% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -3711.952% |
| Avid Bioservices, Inc. | 275.66 Million USD | 29.634% |
| Insmed Incorporated | 1.66 Billion USD | 88.327% |
| MediWound Ltd. | 27.18 Million USD | -613.488% |
| OmniAb, Inc. | 87.4 Million USD | -121.941% |
| Alector, Inc. | 487.66 Million USD | 60.224% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 51.921% |
| Zai Lab Limited | 240.17 Million USD | 19.236% |
| AlloVir, Inc. | 45.01 Million USD | -330.914% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 69.213% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -533.95% |
| Aura Biosciences, Inc. | 29.22 Million USD | -563.688% |
| Immunic, Inc. | 25.36 Million USD | -664.648% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -180.166% |
| Veracyte, Inc. | 93.71 Million USD | -106.976% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -7313.078% |
| FibroGen, Inc. | 585.72 Million USD | 66.883% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1015.895% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -130.852% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -29601.903% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -3329.89% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -2266.138% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -130.863% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 92.592% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -573.014% |
| XBiotech Inc. | 8.39 Million USD | -2210.063% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1221.723% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -413.001% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1249.023% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -264.754% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 46.579% |
| Agenus Inc. | 462.29 Million USD | 58.041% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -621.53% |
| Theravance Biopharma, Inc. | 169 Million USD | -14.776% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 84.043% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 61.238% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 80.054% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -3116.259% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -48.827% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -52129.169% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -3663.579% |
| Lantern Pharma Inc. | 2.73 Million USD | -6980.238% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -356.683% |
| Ainos, Inc. | 7.39 Million USD | -2523.345% |
| Pluri Inc. | 34.11 Million USD | -468.644% |
| Prothena Corporation plc | 135.01 Million USD | -43.668% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 20.208% |
| Rallybio Corporation | 9.43 Million USD | -1955.702% |
| Kodiak Sciences Inc. | 213.59 Million USD | 9.183% |
| Cue Biopharma, Inc. | 24.44 Million USD | -693.52% |
| MeiraGTx Holdings plc | 319.99 Million USD | 39.381% |
| Annexon, Inc. | 47.11 Million USD | -311.681% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -101.278% |
| Moderna, Inc. | 4.57 Billion USD | 95.757% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -3878.995% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -152.77% |
| Blueprint Medicines Corporation | 918.64 Million USD | 78.884% |
| Immix Biopharma, Inc. | 3.72 Million USD | -5111.911% |
| CalciMedica, Inc. | 4.02 Million USD | -4715.69% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -55.798% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -126.034% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 14.715% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 30.172% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1129.798% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -281.948% |
| Nutriband Inc. | 1.07 Million USD | -17878.736% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1724.283% |
| Vor Biopharma Inc. | 59.1 Million USD | -228.194% |
| Roivant Sciences Ltd. | 773.95 Million USD | 74.937% |
| Alkermes plc | 933.53 Million USD | 79.221% |
| ProKidney Corp. | 29.21 Million USD | -563.938% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -169.49% |
| Arcellx, Inc. | 339.75 Million USD | 42.907% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 89.731% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -29.785% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -119.328% |
| Atai Life Sciences N.V. | 49.16 Million USD | -294.565% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -522.67% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -979.924% |
| MediciNova, Inc. | 3.89 Million USD | -4884.54% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -961.196% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -12795.274% |
| GeoVax Labs, Inc. | 3.51 Million USD | -5410.868% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 51.171% |
| Biomea Fusion, Inc. | 30.69 Million USD | -532.05% |
| RenovoRx, Inc. | 4.46 Million USD | -4243.395% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -521.698% |
| Geron Corporation | 146.12 Million USD | -32.745% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -918.354% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -505.003% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -162.876% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -121.73% |
| Royalty Pharma plc | 6.29 Billion USD | 96.92% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -474.403% |
| Imunon, Inc. | 8.53 Million USD | -2173.931% |
| BioAtla, Inc. | 48.98 Million USD | -295.983% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -48.522% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1264.587% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -2.548% |
| Structure Therapeutics Inc. | 29.05 Million USD | -567.708% |
| 89bio, Inc. | 59.96 Million USD | -223.493% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -476.195% |
| aTyr Pharma, Inc. | 31.59 Million USD | -513.906% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -213.76% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -300.76% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -2277.734% |
| Akari Therapeutics, Plc | 4.58 Million USD | -4131.588% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -993.862% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 88.24% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -42.296% |
| Liquidia Corporation | 73.13 Million USD | -165.219% |
| Entera Bio Ltd. | 1.37 Million USD | -13966.425% |
| GH Research PLC | 6.7 Million USD | -2794.732% |
| Vericel Corporation | 127.7 Million USD | -51.894% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -405.37% |
| Xencor, Inc. | 283.55 Million USD | 31.592% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -6396.889% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -7035.652% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -5062.884% |
| Vaxcyte, Inc. | 167.44 Million USD | -15.842% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -426.008% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -87.362% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -47924.798% |
| Portage Biotech Inc. | 4.45 Million USD | -4259.011% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -12795.274% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -741.544% |
| OncoCyte Corporation | 49.29 Million USD | -293.476% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -4589.029% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -24223.497% |
| Purple Biotech Ltd. | 10 Million USD | -1838.791% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -681.059% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2820.006% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -19.014% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -3252.506% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1497.299% |
| United Therapeutics Corporation | 1.18 Billion USD | 83.592% |
| HilleVax, Inc. | 78.9 Million USD | -145.822% |
| Silo Pharma, Inc. | 1.56 Million USD | -12260.907% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -14423.902% |
| Pharming Group N.V. | 244.07 Million USD | 20.525% |
| Tharimmune, Inc. | 1.81 Million USD | -10587.112% |
| Genprex, Inc. | 3.25 Million USD | -5860.774% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -802.592% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -615.277% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -303.932% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -94063.107% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -54000.427% |
| OKYO Pharma Limited | 7.42 Million USD | -2513.934% |
| Savara Inc. | 37.19 Million USD | -421.553% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -568.537% |
| Curis, Inc. | 57.61 Million USD | -236.694% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -394.839% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -831.726% |
| BeiGene, Ltd. | 2.23 Billion USD | 91.316% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -811.798% |
| Erasca, Inc. | 78.61 Million USD | -146.754% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -29503.267% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -29503.267% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -2673.066% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -11613.527% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1036.356% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -432.083% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -248.658% |
| Adicet Bio, Inc. | 37.12 Million USD | -422.565% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 68.597% |
| Aditxt, Inc. | 28.53 Million USD | -579.865% |
| Adagene Inc. | 45.16 Million USD | -329.442% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -107246.39% |
| Quantum-Si incorporated | 26.63 Million USD | -628.384% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -6275.676% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -68.732% |
| Compugen Ltd. | 55.77 Million USD | -247.783% |
| Generation Bio Co. | 171.63 Million USD | -13.02% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1579.446% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -363.714% |
| Invivyd, Inc. | 51.71 Million USD | -275.101% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -110.896% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2881.837% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -156.935% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -18898.629% |
| 2seventy bio, Inc. | 310.12 Million USD | 37.453% |
| Instil Bio, Inc. | 99.8 Million USD | -94.363% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -436.841% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -14133.198% |
| GeoVax Labs, Inc. | 3.51 Million USD | -5410.868% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1492.622% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1490.645% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -267.094% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 47.553% |
| Evaxion Biotech A/S | 17.61 Million USD | -1001.043% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -20.535% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -26.628% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -798.245% |
| Cingulate Inc. | 10.36 Million USD | -1772.199% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -6953.673% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -420.154% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -680.619% |
| Clearmind Medicine Inc. | 3.61 Million USD | -5273.284% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -312.338% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -752.277% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -866.449% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 17.532% |
| ImmunityBio, Inc. | 1.09 Billion USD | 82.21% |
| Korro Bio, Inc. | 51.75 Million USD | -274.818% |
| Kineta, Inc. | 7.22 Million USD | -2585.904% |
| BioVie Inc. | 9.7 Million USD | -1899.314% |
| Codexis, Inc. | 49.94 Million USD | -288.371% |
| Celularity Inc. | 102.92 Million USD | -88.456% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -72.578% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -101.54% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -56093.329% |
| Cibus, Inc. | 206.11 Million USD | 5.89% |
| IN8bio, Inc. | 8.77 Million USD | -2111.309% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -116.634% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1317.021% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 92.549% |
| Eyenovia, Inc. | 19.78 Million USD | -880.653% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -9.538% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2425.4% |
| Elevation Oncology, Inc. | 34.28 Million USD | -465.825% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -704.913% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1530.324% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 21.0% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1928.401% |
| Moolec Science SA | 13.94 Million USD | -1290.972% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -349.518% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -283.868% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -387.671% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -2226.688% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -65787.244% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -7784.299% |
| Humacyte, Inc. | 114.67 Million USD | -69.15% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -633.008% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -16118.729% |
| Genelux Corporation | 8.42 Million USD | -2203.753% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2729.288% |
| Notable Labs, Ltd. | 4.42 Million USD | -4281.658% |
| Immunovant, Inc. | 48.95 Million USD | -296.233% |
| Quantum-Si incorporated | 26.63 Million USD | -628.384% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -6151.241% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -162.623% |
| Acasti Pharma Inc. | 11.55 Million USD | -1578.429% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -758.007% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -736.68% |
| PepGen Inc. | 34.63 Million USD | -460.122% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -2677.434% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2166.818% |
| Immuneering Corporation | 12 Million USD | -1515.342% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -61703.746% |
| Belite Bio, Inc | 4.21 Million USD | -4506.412% |
| XOMA Corporation | 145.58 Million USD | -33.244% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -7889.127% |
| Bionomics Limited | 10.15 Million USD | -1809.453% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -746.576% |
| uniQure N.V. | 624.01 Million USD | 68.915% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -107246.39% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -13.98% |
| Forte Biosciences, Inc. | 3.66 Million USD | -5191.217% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -74339.238% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2774.996% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2425.4% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1015.895% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1735.503% |
| Altimmune, Inc. | 16.54 Million USD | -1072.698% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -3879.811% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -746.576% |
| Peak Bio, Inc. | 20.75 Million USD | -834.673% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -75.603% |
| Benitec Biopharma Inc. | 4.96 Million USD | -3809.23% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -22.892% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -158.036% |
| Zura Bio Limited | 21.29 Million USD | -811.028% |
| PolyPid Ltd. | 17.46 Million USD | -1010.465% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -158.036% |
| argenx SE | 444.95 Million USD | 56.405% |
| Immunome, Inc. | 28.65 Million USD | -576.865% |
| Verona Pharma plc | 58.84 Million USD | -229.661% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1240.261% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1205.445% |
| CervoMed Inc. | 2.59 Million USD | -7372.839% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1423.053% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1741.253% |
| Moolec Science SA | 13.94 Million USD | -1290.972% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -8177.178% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1522.416% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1429.297% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -398.294% |
| Achilles Therapeutics plc | 19.08 Million USD | -916.273% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -752.277% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1236.751% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 51.66% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -497.345% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1386.509% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -3592.671% |
| Beam Therapeutics Inc. | 478.38 Million USD | 59.452% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 51.256% |
| AEON Biopharma, Inc. | 159.88 Million USD | -21.319% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -612.414% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -647.182% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -2451.572% |
| NeurAxis, Inc. | 1.91 Million USD | -10041.269% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 0.9% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1354.856% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -722.351% |
| Palisade Bio, Inc. | 2.73 Million USD | -6982.001% |
| Nutriband Inc. | 1.07 Million USD | -17878.736% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -0.999% |
| Neurogene Inc. | 36.54 Million USD | -430.729% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -7833.579% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -307.085% |
| Athira Pharma, Inc. | 30.05 Million USD | -545.36% |
| HCW Biologics Inc. | 15.05 Million USD | -1188.711% |
| XOMA Corporation | 145.58 Million USD | -33.244% |
| Nektar Therapeutics | 267.04 Million USD | 27.362% |
| Arvinas, Inc. | 644.6 Million USD | 69.908% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -993.862% |
| Merus N.V. | 102.15 Million USD | -89.891% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -32.543% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -103.928% |
| Rezolute, Inc. | 11.73 Million USD | -1553.111% |
| Clene Inc. | 38.95 Million USD | -398.0% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -6712.438% |
| BeyondSpring Inc. | 48.26 Million USD | -301.865% |
| Synlogic, Inc. | 32.89 Million USD | -489.682% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1227.421% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -11771.236% |
| Peak Bio, Inc. | 20.75 Million USD | -834.673% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -205.671% |
| Krystal Biotech, Inc. | 39.71 Million USD | -388.432% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 48.499% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -94.816% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -44726.518% |
| MannKind Corporation | 721.36 Million USD | 73.11% |
| Ikena Oncology, Inc. | 22.33 Million USD | -768.484% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -9198.945% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -89.079% |
| Gossamer Bio, Inc. | 249.14 Million USD | 22.144% |
| CohBar, Inc. | 1.03 Million USD | -18666.338% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1714.725% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -918.354% |
| Legend Biotech Corporation | 589.93 Million USD | 67.119% |
| Mural Oncology plc | 37.92 Million USD | -411.432% |
| Disc Medicine, Inc. | 22.87 Million USD | -747.983% |
| Champions Oncology, Inc. | 28.03 Million USD | -591.907% |
| REGENXBIO Inc. | 262.22 Million USD | 26.028% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -5674.209% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1447.599% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1344.174% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -814.765% |
| Vaxart, Inc. | 34.02 Million USD | -470.098% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -851.363% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -579.857% |
| Cellectis S.A. | 249.57 Million USD | 22.277% |
| Longeveron Inc. | 5.33 Million USD | -3534.551% |
| Repare Therapeutics Inc. | 41.81 Million USD | -363.847% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 91.935% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -221.323% |
| Revolution Medicines, Inc. | 262.39 Million USD | 26.075% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -9106.265% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2148.736% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1543.725% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1281.3% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -8917.945% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 96.233% |
| Denali Therapeutics Inc. | 122.96 Million USD | -57.752% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -3385.709% |
| Veru Inc. | 32.81 Million USD | -491.161% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2723.934% |
| Cingulate Inc. | 10.36 Million USD | -1772.199% |
| Passage Bio, Inc. | 39.26 Million USD | -394.055% |
| Context Therapeutics Inc. | 4.19 Million USD | -4527.605% |
| Exicure, Inc. | 8.54 Million USD | -2168.991% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -557.367% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1749.857% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -780.069% |
| Nuvalent, Inc. | 31.82 Million USD | -509.547% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2949.157% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -207.791% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -977.644% |
| OmniAb, Inc. | 87.4 Million USD | -121.941% |
| Anew Medical, Inc. | 8.24 Million USD | -2253.564% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -406.609% |
| Lipocine Inc. | 2.63 Million USD | -7270.948% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -638.337% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -382.383% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -628.089% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -125.15% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -3491.483% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -134.421% |
| Ocugen, Inc. | 23.98 Million USD | -708.806% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -317.989% |
| Q32 Bio Inc. | 233.12 Million USD | 16.794% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2039.598% |
| Alumis Inc. Common Stock | 53.5 Million USD | -262.558% |
| Equillium, Inc. | 27.95 Million USD | -593.837% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 6.107% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -3347.442% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -3062.841% |
| Dominari Holdings Inc. | 4.63 Million USD | -4085.027% |
| Edesa Biotech, Inc. | 1.84 Million USD | -10432.803% |
| vTv Therapeutics Inc. | 29.56 Million USD | -556.056% |
| Bio-Techne Corporation | 744.34 Million USD | 73.94% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -53.828% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 43.686% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -378.068% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -569.876% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -110.022% |
| Nkarta, Inc. | 105.6 Million USD | -83.689% |
| BioCardia, Inc. | 4.59 Million USD | -4126.057% |
| Iterum Therapeutics plc | 32.66 Million USD | -493.889% |